Human Bocavirus Infection in Children With Respiratory Tract Disease

Brieu, Nathalie; Guyon, G.; Segondy, Michel; Foulongne, Vincent

doi:10.1097/inf.0b013e31817acfaa

Cited by 101 publications

(127 citation statements)

References 22 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Also, we found that the longer hospitalization period was accompanied with high HBoV viral load patients and that was in agreement with Deng et al, (2012).These results suggest that HBoV is a significant pathogen in young children with ALRI that was underestimated in our region. We detected three NPA samples with HBoV positive PCR results that were accompanied by bacterial co-infection and were associated with low virus load that result was in agreement with Jiang et al, (2016) who reported that co-infection was more frequently found among patients with low virus load than those with high virus load suggesting HBoV as causative agent of ALRI, this results were in agreement with the studies of Brieu et al, (2008) and Kaida et al, (2010).…”

Section: Resultssupporting

confidence: 82%

Detection of Human Bocavirus in Egyptian Children Suffering from Acute Lower Respiratory Tract Infection

Atef¹,

Elbehedy²

2017

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 82%

Detection of Human Bocavirus in Egyptian Children Suffering from Acute Lower Respiratory Tract Infection

Atef¹,

Elbehedy²

2017

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

“…1). Previous studies detected HBoV mainly in children less than 5 years old and mostly in infants less than 2 years old (Choi et al, 2006;Kaplan et al, 2006;Kesebir et al, 2006;Kleines et al, 2007;Brieu et al, 2008;Canducci et al, 2008;Cilla et al, 2008). However, a recent report (Guido et al, 2011) and the present work confirm that HBoV1 is also a frequent virus in adults with respiratory disease.…”

Section: Resultscontrasting

confidence: 48%

High frequency of human bocavirus 1 DNA in infants and adults with lower acute respiratory infection

Ghietto

Cámara

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

Instituto de Virología 'Dr J. M. Vanella', Facultad de Ciencias Mé dicas, Universidad Nacional de Có rdoba, ArgentinaHuman bocavirus (HBoV) is a parvovirus with a possible aetiological role in respiratory disease that is currently under investigation. We detected HBoV1 in children and adults hospitalized with acute disease of the lower respiratory tract. HBoV genome was detected by PCR in nasopharyngeal swabs collected from 75 patients aged 0-89 years during 2010. HBoV was found in 17/75 (22.7 %) patients, 64.7 % of them infants younger than 1 year old and 29.4 % adults older than 30 years [the bimodal age distribution among HBoV-positive (HBoV + ) patients was statistically significant, P,0.001]. Of all HBoV + cases, 35.3 % were co-infected; all coinfections occurred in children (¡13 years old) and 83.3 % of them were HBoV-respiratory syncytial virus (RSV) co-infections. Among infants younger than 1 year, 50 % HBoV + specimens were co-infected, all of them with RSV. The rate of co-infection in infants was significantly higher compared to the frequency of co-infection in the whole cohort (P50.003). The results suggest that HBoV1 is involved in acute respiratory disease. Interplay between HBoV1 and RSV cannot be discarded as a cause of elevated percentages of co-detections in infants. INTRODUCTIONHuman bocavirus (HBoV) is a parvovirus first identified in 2005 in nasopharyngeal aspirates of children with lower respiratory tract infection (Allander et al., 2005). Since then, it has been associated with upper and lower acute respiratory infection (ARI), a leading cause of acute illnesses worldwide and the most important cause of mortality in infants and young children and disabilityadjusted life-years lost in developing countries (Simoes et al., 2006; WHO, 2009). To date, four species of HBoV have been proposed, and the name human bocavirus 1 (HBoV1) was suggested for the originally discovered virus. HBoV1 is linked to respiratory disease, while it is believed that HBoV2-4 are associated with gastroenteritis (Kapoor et al., 2010). With a ubiquitous distribution, the presence of HBoV DNA has been reported mostly in children with ARI in a variable range from 1.5 to 19 % (Allander, 2008), although recently even higher prevalence (33 %) has been observed in ill children (Martin et al., 2010). Although the virus is associated with ARI, the elevated rates of coinfection with other respiratory viruses with well-established pathogenic potential (Kaplan et al., 2006;Allander et al., 2007;Fry et al., 2007; Gerna et al., 2007;Kleines et al., 2007; Christensen et al., 2008 Christensen et al., , 2010Cilla et al., 2008;Pilger et al., 2011), the detection in asymptomatic individuals (Christensen et al., 2010) and the possibility of a persistent infection (Martin et al., 2010) make it difficult to allocate a causative role for HBoV in respiratory disease. Not only is the aetiological capacity of HBoV under investigation, but the natural history of the infection is still unknown. In addition, the impact of HBoV on the global epid...

show abstract

“…21,27,28,64 Studies of nasopharyngeal samples have shown persistence of HBoV1 DNA for several months. [65][66][67][68] HBoV1 seroprevalence ranges from 25% in infants younger than 1 year to 93% and 100% in children of 3 (ref. 28) to 7 (ref.…”

Section: Discussionmentioning

confidence: 99%

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Among the immunocompetent, infections with parvovirus B19 (B19V) and human bocavirus (HBoV) 1 range clinically from asymptomatic to severe, while following allogeneic hematopoietic SCT (HSCT) B19V can cause a persistent severe illness. The epidemiology and clinical impact of HBoV1 and the other emerging parvovirus 4 (PARV4) among immunocompromised patients have not been established. To determine the occurrence and clinical spectrum of B19V, PARV4 and HBoV1 infections, we performed a longitudinal molecular surveillance among 53 allogeneic HSCT recipients for pre-and post-HSCT DNAemias of these parvoviruses. Quantitative real-time PCR showed B19V DNA in sera of 16 (30%) patients, at mean levels of 4.6 Â 10 3 , 9.9 Â 10 7 , 1.1 Â 10 10 and 1.6 Â 10 2 B19V DNA copies/mL pre-HSCT (9/53), and at 1 (6/53), 2 (4/53) and 3 months (1/25) post HSCT, respectively. However, no clinical manifestation correlated with the presence of B19V viremia. All B19V sequences were of genotype 1. None of the sera investigated contained PARV4 or HBoV1 DNAs. Our data demonstrate B19V viremia to be frequent among pediatric allogeneic HSCT recipients, yet without apparent clinical correlates. PARV4 or HBoV1 viremias were not seen in these immunocompromised patients.

show abstract

Human Bocavirus Infection in Children With Respiratory Tract Disease

Cited by 101 publications

References 22 publications

Detection of Human Bocavirus in Egyptian Children Suffering from Acute Lower Respiratory Tract Infection

Detection of Human Bocavirus in Egyptian Children Suffering from Acute Lower Respiratory Tract Infection

High frequency of human bocavirus 1 DNA in infants and adults with lower acute respiratory infection

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Contact Info

Product

Resources

About